-
麻豆社Website
- Facts, figures and industry data
Facts, figures and industry data
Headline pharmaceutical industry statistics
The figures below provide a snapshot of key biopharmaceutical sector statistics relating to the UK鈥檚 economy and health systems. Sub-national statistics can be found via the ABPI鈥檚 interactive . International comparisons are available in several of the source documents and within the Government鈥檚 Life Sciences Competitiveness Indicators . Statistics on the economic and health system benefits which can be delivered through a supportive policy environment are available in the ABPI鈥檚 manifesto.听听
Economic statistics
£17.6bn
direct Gross Value Added (GVA) [1]
£45bn
R&D spillovers [2]
£9bn
investment in UK R&D (more than UKRI’s entire annual budget) [3]
£26.1bn
exports [4]
126,000
jobs [5]
£46.7bn
turnover [6]
Over 3,000
manufacturing and research sites combined [6]
£355m
revenue [7]
£28.6m
cost savings for the NHS in England through industry clinical trials in 2018/19 [7]
Health system statistics
9%
Amount the UK invests of overall healthcare spending on medicines – a significantly lower proportion than other advanced healthcare systems such as the United States (14%), France (15%), Germany (17%) and Japan (17%) [8]
42,088
patients recruited to industry clinical trials in 2022/23 (increasing from 36,722 in 2021/22, but below pre-pandemic levels of 58,048 in 2017/18) [9]
411
industry clinical trials initiated in the UK in 2022 (increasing from 394 trials in 2021, but below the 2015 peak of 690 trials) [10]
70%
UK average uptake of medicines launched between 2018-22 is 70% of the average uptake of comparator countries three years after launch [11]. Across the UK, variation persists. For example, patients in Derby ICS are 3x less likely to access new NICE-approved medicines compared to Norfolk or Surrey ICSs [12]
References:
[1] ONS, 鈥楻egional gross value added (balanced) by industry: all ITL regions鈥�, 2021. Methodology available at:
[2] ABPI, 鈥楲ife Sciences Superpower鈥�, June 2022, available at www.abpi.org.uk/publications/abpi-life-sciences-superpower-report/
[3] ONS, 鈥楤usiness Enterprise Research and Development statistics 2022鈥� available at
[4] Office for National Statistics, 鈥楾rade in goods: country-by-commodity exports鈥�, accessed 17 July 2024, available at 听
[5] ONS, 鈥業ndustry Census Data 2021鈥�, available at: (methodology available at )
[6] OLS, 鈥楤ioscience and health technology sector statistics 2021 to 2022鈥�, available at: 听
[7] NIHR, 鈥業mpact and value of the NIHR Clinical Research Network 2019鈥�, accessed January 2024, available at
[8] The King鈥檚 Fund, 鈥楬ow does the NHS compare to the health care systems of other countries?鈥�, June 2023, available at:
[9] Number of participants recruited to industry research studies in
the UK per year, as reported by the NIHR CRN, NRS, HCRW, and NICRN听(2017/18-2022/23)
[10] Clarivate data, included in the ABPI鈥檚 report: 鈥楪etting back on track: Restoring the UK鈥檚 global position in industry clinical trials鈥�, November 2023, available at www.abpi.org.uk/publications/getting-back-on-track-restoring-the-uk-s-global-position-in-industry-clinical-trials/
[11] Uptake ratios three years post-reimbursement (n=36 medicines), Office for Life Sciences, 鈥楲ife Sciences Competitiveness Indicators 2024鈥� available at: 听
[12] Local Uptake of NICE Approved Medicines in England and Wales, A Summary of听Insights 鈥� June 2022, IQVIA report, commissioned by the ABPI
Industry data
Clinical trials
Medicines and vaccines have helped deliver incredible improvements in patient health. This section looks at expenditure on R&D in the UK and around the world, clinical trials by phase and by therapy area and research intensity.
Cancer in the UK - Digital Data Toolkit
Cancer survival in the UK has improved over recent years, with more people living five years or more with the disease than ever before. However, despite this progress, cancer remains one of the UK’s leading causes of death. More can be done to improve cancer outcomes for those affected. By looking at how the UK compares to other European countries, we can begin to consider how this can be achieved.
